ChannelDynamics
Measure the performance of your sales force and marketing channels, adapt your commercial strategy and gain real world competitive insights.
-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Integrated Global Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Public Health and Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety and quality.
COMPLIANCE OVERVIEWIntegrated Global Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSFEATURED INNOVATIONS
-
Connected Intelligence
-
AI & Machine Learning
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Genomics
WHO WE ARE
- Our Story
- Commitment to Public Health
- Code of Conduct
- Environmental Social Governance
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
AI & Machine Learning with a healthcare IQ.
Artificial intelligence is accelerating opportunities. Realizing the benefits for healthcare requires the right expertise. Together, we can solve the problems of today, and drive the breakthroughs of tomorrow.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
Unlock the power of genomic research.
IQVIA enables genomic research via global access to a network of genomic-clinical data, proprietary technologies that enable federated analytics, and therapeutic area & bioinformatics expertise to help you answer your most pressing research questions.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBS
White Paper
Opiate of the Masses
Apr 11, 2018
In response to rising codeine-related deaths, Australia’s Therapeutic Goods Administration (TGA) recently restricted access to the popular painkiller which can now only be obtained via prescription. This up-schedule represents a significant and rare disruption in both the OTC and pain markets. This report identifies key impacts and major shifts in the pain markets caused by the up-scheduling of codeine.
Codeine is an old and popular opioid drug that relieves pain and suppresses coughing. In Australia, codeine is usually marketed in combination analgesics and cough-and-cold formulations. Until 2018, only products that contained more than 30 mg of codeine per dose were assigned to the S4 Poisons Schedule, where they were accessible through a prescription. Over-the-counter (OTC) products containing codeine were listed on the less restrictive pharmacy-only S3 or S2 schedule. These products typically contained 8 to 12 mg per dose and were always supplied in combination with other drugs, such as ibuprofen or paracetamol.
The availability of codeine without the requirement of a prescription has obvious benefits for the average consumer as it allows fast pain relief without a doctor’s intervention. However, new research suggests that low-doses of codeine (<30 mg), such as those found in OTC S3 and S2 products, are non-therapeutic and are no better at relieving pain than analogous products without codeine. This level of access further creates the potential for abuse and self-harm, which in extreme cases have led to death. Increasing mortality due to codeine abuse prompted the Therapeutic Goods Administration (TGA) to reschedule all codeine to at least S4, which took effect on the 1st of February, 2018.
This up-schedule represents a significant and rare disruption in both the OTC and pain markets. Observing and measuring the impacts the up-schedule will have on codeine use will be of critical importance to industry strategists, policymakers, and public health leaders.
We assessed the impacts the up-scheduling of codeine had on consumers, pharmacists, and manufacturers. We used our best-in-class data assets to study the distribution of non-prescription codeine products across Australia’s pharmacies, which allowed us to understand the commercial impacts of the TGA’s decision. We also used Channel DynamicsTM, which tracks pharmacist recalls of manufacturer promotional visits, to understand how promotional strategies to pharmacies have shifted. To find out how pharmacists prepared for the schedule change, we surveyed 200 pharmacists nationally as part of IQVIA’s monthly Medibus survey. This analysis was supplemented with a series of discussions with pharmacists in New South Wales, who were asked to provide their perspective on the expected impact of change on patient outcomes, opioid addiction, and their businesses.
In summary, we identified five key findings:- Harm from opioid abuse is increasing in Australia. Codeine related deaths were recently found to have doubled between 2000 and 2009.
- The TGA estimates that up-scheduling codeine to prescription-only will result in $5.6 billion of net benefit over the next decade in the form of harm prevention, improved quality of life and a reduction in codeine long-term dependency.
- OTC codeine sales declined in the months leading up to the up-schedule as ibuprofen-paracetamol combinations increased. Prescription-only codeine sales remain steady.
- Manufacturers adjusted to the change by visiting pharmacies more frequently to discuss the schedule change. Manufacturers offered deals to pharmacies in an effort to clear OTC stock.
- Pharmacies expect the up-schedule to negatively affect their revenue. They plan to use this opportunity to engage frequent and cyclical users on codeine-free pain management plans.
DOWNLOAD TO LEARN MORE
Related solutions
Pharmaceutical Manufacturers
Solutions for you to drive healthcare forward™
Therapeutic & Specialty Expertise
Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.